In the following video, Motley Fool health-care bureau chief Brenton Flynn takes a look at two different companies with drugs facing FDA approval decisions in February. He discusses ImmunoGen (IMGN) and its drug T-DM1, where approval is already expected by the market, as well as Dynavax (DVAX 1.72%) and its hepatitis B vaccine Heplisav. Dynavax is the wildcard of this group, and Brenton gives his prediction for whether or not the drug will be approved.